Sandoz confirms E.C. granted marketing authorization for Ranluspec

Sandoz (SDZNY) confirmed that the European Commission, E.C., has granted marketing authorization for Ranluspec. Ranluspec is developed, manufactured and registered by Lupin and was approved based on the review of a comprehensive data package. Claire D’Abreu-Hayling, Chief Scientific Officer, Sandoz, said: “Retinal diseases, including nAMD, place a significant burden on millions of patients, families and caregivers in Europe. The approval of Ranluspec reinforces our commitment to expanding the availability of high-quality biosimilars and transforming healthcare by ensuring that patients can access these life-changing treatments.”